57 Citations (Scopus)

Abstract

Human immunodeficiency virus type 1 (HIV-1)-associated neurocognitive disorders (HAND) can affect up to 50% of infected people during the disease course. While antiretroviral therapies have substantively increased the quality of life and reduced HIV-1-associated dementia, less severe minor cognitive and motor deficits continue. Trafficking of HIV-1 into the central nervous system (CNS), peripheral immune activation, dysregulated glial immunity, and diminished homeostatic responses are the disease-linked pathobiologic events. Monocyte-macrophage passage into the CNS remains an underlying force for disease severity. Monocyte phenotypes may change at an early stage of cell maturation and immune activation of hematopoietic stem cells. Activated monocytes are pulled into the brain in response to chemokines made as a result of glial inflammatory processes, which in turn, cause secondary functional deficits in neurons. Current therapeutic approaches are focused on adjunctive and brain-penetrating antiretroviral therapies. These may attenuate virus-associated neuroinflammatory activities thereby decreasing the severity and frequency of HAND.

Original languageEnglish (US)
Pages (from-to)542-548
Number of pages7
JournalNeurobiology of Disease
Volume37
Issue number3
DOIs
StatePublished - Mar 1 2010

Fingerprint

HIV-1
Monocytes
Neuroglia
Central Nervous System
Brain
Therapeutics
Hematopoietic Stem Cells
Chemokines
Dementia
Immunity
Macrophages
Quality of Life
Viruses
Phenotype
Neurons
Neurocognitive Disorders

Keywords

  • Adaptive immunity
  • Adjunctive therapies
  • Blood-brain barrier
  • Chemokines
  • Cognitive dysfunction
  • HIV-1-associated neurocognitive disorders
  • Hematopoietic stem cells
  • Innate immunity
  • Microglia
  • Neuroinflammation
  • Proinflammatory cytokines

ASJC Scopus subject areas

  • Neurology

Cite this

HIV-1 neuroimmunity in the era of antiretroviral therapy. / Kraft-Terry, Stephanie D.; Stothert, Andrew R.; Buch, Shilpa J; Gendelman, Howard Eliot.

In: Neurobiology of Disease, Vol. 37, No. 3, 01.03.2010, p. 542-548.

Research output: Contribution to journalReview article

Kraft-Terry, Stephanie D. ; Stothert, Andrew R. ; Buch, Shilpa J ; Gendelman, Howard Eliot. / HIV-1 neuroimmunity in the era of antiretroviral therapy. In: Neurobiology of Disease. 2010 ; Vol. 37, No. 3. pp. 542-548.
@article{3787cb5b13104197bd803c7ac6e40d52,
title = "HIV-1 neuroimmunity in the era of antiretroviral therapy",
abstract = "Human immunodeficiency virus type 1 (HIV-1)-associated neurocognitive disorders (HAND) can affect up to 50{\%} of infected people during the disease course. While antiretroviral therapies have substantively increased the quality of life and reduced HIV-1-associated dementia, less severe minor cognitive and motor deficits continue. Trafficking of HIV-1 into the central nervous system (CNS), peripheral immune activation, dysregulated glial immunity, and diminished homeostatic responses are the disease-linked pathobiologic events. Monocyte-macrophage passage into the CNS remains an underlying force for disease severity. Monocyte phenotypes may change at an early stage of cell maturation and immune activation of hematopoietic stem cells. Activated monocytes are pulled into the brain in response to chemokines made as a result of glial inflammatory processes, which in turn, cause secondary functional deficits in neurons. Current therapeutic approaches are focused on adjunctive and brain-penetrating antiretroviral therapies. These may attenuate virus-associated neuroinflammatory activities thereby decreasing the severity and frequency of HAND.",
keywords = "Adaptive immunity, Adjunctive therapies, Blood-brain barrier, Chemokines, Cognitive dysfunction, HIV-1-associated neurocognitive disorders, Hematopoietic stem cells, Innate immunity, Microglia, Neuroinflammation, Proinflammatory cytokines",
author = "Kraft-Terry, {Stephanie D.} and Stothert, {Andrew R.} and Buch, {Shilpa J} and Gendelman, {Howard Eliot}",
year = "2010",
month = "3",
day = "1",
doi = "10.1016/j.nbd.2009.12.015",
language = "English (US)",
volume = "37",
pages = "542--548",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - HIV-1 neuroimmunity in the era of antiretroviral therapy

AU - Kraft-Terry, Stephanie D.

AU - Stothert, Andrew R.

AU - Buch, Shilpa J

AU - Gendelman, Howard Eliot

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Human immunodeficiency virus type 1 (HIV-1)-associated neurocognitive disorders (HAND) can affect up to 50% of infected people during the disease course. While antiretroviral therapies have substantively increased the quality of life and reduced HIV-1-associated dementia, less severe minor cognitive and motor deficits continue. Trafficking of HIV-1 into the central nervous system (CNS), peripheral immune activation, dysregulated glial immunity, and diminished homeostatic responses are the disease-linked pathobiologic events. Monocyte-macrophage passage into the CNS remains an underlying force for disease severity. Monocyte phenotypes may change at an early stage of cell maturation and immune activation of hematopoietic stem cells. Activated monocytes are pulled into the brain in response to chemokines made as a result of glial inflammatory processes, which in turn, cause secondary functional deficits in neurons. Current therapeutic approaches are focused on adjunctive and brain-penetrating antiretroviral therapies. These may attenuate virus-associated neuroinflammatory activities thereby decreasing the severity and frequency of HAND.

AB - Human immunodeficiency virus type 1 (HIV-1)-associated neurocognitive disorders (HAND) can affect up to 50% of infected people during the disease course. While antiretroviral therapies have substantively increased the quality of life and reduced HIV-1-associated dementia, less severe minor cognitive and motor deficits continue. Trafficking of HIV-1 into the central nervous system (CNS), peripheral immune activation, dysregulated glial immunity, and diminished homeostatic responses are the disease-linked pathobiologic events. Monocyte-macrophage passage into the CNS remains an underlying force for disease severity. Monocyte phenotypes may change at an early stage of cell maturation and immune activation of hematopoietic stem cells. Activated monocytes are pulled into the brain in response to chemokines made as a result of glial inflammatory processes, which in turn, cause secondary functional deficits in neurons. Current therapeutic approaches are focused on adjunctive and brain-penetrating antiretroviral therapies. These may attenuate virus-associated neuroinflammatory activities thereby decreasing the severity and frequency of HAND.

KW - Adaptive immunity

KW - Adjunctive therapies

KW - Blood-brain barrier

KW - Chemokines

KW - Cognitive dysfunction

KW - HIV-1-associated neurocognitive disorders

KW - Hematopoietic stem cells

KW - Innate immunity

KW - Microglia

KW - Neuroinflammation

KW - Proinflammatory cytokines

UR - http://www.scopus.com/inward/record.url?scp=75949100300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75949100300&partnerID=8YFLogxK

U2 - 10.1016/j.nbd.2009.12.015

DO - 10.1016/j.nbd.2009.12.015

M3 - Review article

C2 - 20044002

AN - SCOPUS:75949100300

VL - 37

SP - 542

EP - 548

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

IS - 3

ER -